Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun 8;7(10):1355-68.
doi: 10.4254/wjh.v7.i10.1355.

Review on Immunosuppression in Liver Transplantation

Affiliations
Free PMC article
Review

Review on Immunosuppression in Liver Transplantation

Maryam Moini et al. World J Hepatol. .
Free PMC article

Abstract

The optimal level of immunosuppression in solid organ transplantation, in particular for the liver, is a delicate balance between the benefit of preventing rejection and the adverse side effects of immunosuppression. There is uncertainty about when this level is achieved in any individual recipient. Immunosuppression regimens vary between individual centers and changes with time as new agents and data are available. Presently concerns about the adverse side effects of calcineurin inhibitor, the main class of immunosuppressive agents used in liver transplantation (LT), has led to consideration of the use of antibody induction therapies for patients at higher risk of developing adverse side effects. The longevity of the transplanted organ is potentially improved by better management of rejection episodes and special consideration for tailoring of immunosuppression to the individual with viral hepatitis C, hepatocellular carcinoma or pregnancy. This review provides an overview of the current strategies for post LT immunosuppression and discusses modifications to consider for special patient populations.

Keywords: Immunosuppression; Immunosuppression induction; Immunosuppression maintenance; Liver transplantation.

Figures

Figure 1
Figure 1
The cellular site of action of the immunosuppressive agents commonly used in solid organ transplantation. AZA: Azathioprine; CsA: Cyclosporine; IL-2: Interleukin-2; IL-2Ra: Interleukin-2 receptor antagonist; MMF: Mycophenolate mofetil; TAC: Tacrolimus; TOR: Target of rapamycin.

Similar articles

See all similar articles

Cited by 16 articles

See all "Cited by" articles
Feedback